Novavax (NVAX) Preferred Stock Liabilities (2020)
Novavax's (NVAX) quarterly Preferred Stock Liabilities came in at $199.8 million in Q3 2020, little changed quarter-over-quarter from $199.8 million in Q2 2020.
Novavax (NVAX) Preferred Stock Liabilities (2020) Analysis & Trends
Novavax's Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $199.8 million for Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Novavax | 788.01 Mn | -2.33 Mn | 108.82 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 199.82 Mn |
| Jun 30, 2020 | 199.82 Mn |